



# DOCTOR'S DIGEST<sup>®</sup>

Delivering In-depth

Practice Solutions

From the Experts

Nov/Dec 2010

[www.doctorsdigest.net](http://www.doctorsdigest.net)

## Your Office in 2015

The Impact of Healthcare Reform

A Day in the Office

Key Standards and Rules

EHRs and Other Tech Trends

The Green Office



**Coming Soon! *Doctor's Digest Digital Editions.***

Pre-register now for your FREE digital subscription on the iPad and Web and receive a FREE 2GB Credit card-sized USB drive. See page 71.

PERMIT NO. 356  
MECHANICSBURG, PA  
PAID  
U.S. POSTAGE  
PRESORTED STD

HELP PROVIDE YOUR HIGH-RISK PATIENTS\*  
WITH STRONG CV SUPPORT

## LIPITOR PUTS THE POWER TO HELP CHANGE THE OUTCOME OF CVD IN YOUR HANDS BY REDUCING THE RISK OF MI AND STROKE

LIPITOR provides potent<sup>†</sup> mean LDL-C reductions >50%, and, unlike Crestor<sup>®</sup>,<sup>1</sup> has CV outcomes indications for high-risk patients with CHD or patients with type 2 diabetes and  $\geq 1$  risk factor.

AVAILABLE AS A GENERIC AFTER 11/30/2011—NOW IS THE TIME TO PRESCRIBE LIPITOR FOR MANY OF YOUR HIGH-RISK PATIENTS

### Important Safety Information

LIPITOR is contraindicated in patients with active liver disease or unexplained persistent elevations of hepatic transaminases; in women who are or may become pregnant or who are nursing; in patients with hypersensitivity to any component of this medication.

Rare cases of rhabdomyolysis have been reported with LIPITOR and other statins. Tell patients to promptly report muscle pain, tenderness, or weakness. Predisposing factors include advanced age ( $\geq 65$ ), uncontrolled hypothyroidism, and renal impairment. Patients with a history of renal impairment merit closer monitoring. In cases of myopathy or rhabdomyolysis, therapy should be temporarily withheld or discontinued.

The concomitant use of higher doses of LIPITOR with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (eg, clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis. Lower doses of LIPITOR should be considered. Physicians should carefully monitor patients for signs or symptoms of myopathy early during therapy and when titrating the dose of either drug.

It is recommended that liver function tests be performed prior to and 12 weeks following both the initiation of therapy and any elevation of dose, and periodically thereafter. If ALT or AST values  $>3 \times$  ULN persist, dose reduction or withdrawal is recommended.

In a post hoc analysis of the SPARCL study in patients without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the LIPITOR 80-mg group compared with placebo (2.3% vs 1.4%). Some baseline characteristics, including hemorrhagic and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the LIPITOR group.

Please see brief summary of prescribing information on adjacent page.

The most commonly reported adverse reactions with LIPITOR in placebo-controlled trials were: nasopharyngitis, arthralgia, diarrhea, pain in extremity, and urinary tract infection.

### LIPITOR Indications

LIPITOR is indicated as an adjunct to diet to reduce the risk of myocardial infarction (MI), stroke, revascularization procedures, and angina in adult patients with multiple risk factors but without clinically evident coronary heart disease (CHD); to reduce the risk of MI and stroke in patients with type 2 diabetes and without clinically evident CHD, but with multiple risk factors; to reduce the risk of nonfatal MI, fatal and nonfatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adult patients with clinically evident CHD.

LIPITOR, as an adjunct to diet, is also indicated to reduce elevated total-C, LDL-C, apo B, and TG levels; and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia.

Reference: 1. Crestor [package insert], Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010.

\*Patients with type 2 diabetes and  $\geq 1$  risk factor; or CHD.

<sup>†</sup>LIPITOR has been shown to reduce LDL-C by >50% with a 40-mg starting dose. LIPITOR 40 mg may be a starting dose for patients who require an LDL-C reduction of >45%.

Crestor (rosuvastatin calcium) is a registered trademark of the AstraZeneca group of companies.



**LIPITOR**  
atorvastatin calcium  
POWERED BY  
OUTCOMES



U.S. Pharmaceuticals

**LIPITOR®** (Atorvastatin Calcium) Tablets  
**Brief Summary of Prescribing Information**

**CONTRAINDICATIONS:** Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels. Hypersensitivity to any component of this medication.

**Pregnancy**—Women who are pregnant or may become pregnant. LIPITOR may cause fetal harm when administered to a pregnant woman. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. There are no adequate and well-controlled studies of LIPITOR use during pregnancy; however in rare reports, congenital anomalies were observed following intrauterine exposure to statins. In rat and rabbit animal reproduction studies, atorvastatin revealed no evidence of teratogenicity. LIPITOR SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this drug, LIPITOR should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see *Use in Specific Populations* in full prescribing information]. **Nursing mothers**—It is not known whether atorvastatin is excreted into human milk; however a small amount of another drug in this class does pass into breast milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require LIPITOR treatment should not breastfeed their infants [see *Use in Specific Populations* in full prescribing information].

**WARNINGS AND PRECAUTIONS: Skeletal Muscle**—Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with LIPITOR and with other drugs in this class. A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects. Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values >10 times ULN. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK. Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. LIPITOR therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, combination of ritonavir plus saquinavir or lopinavir plus ritonavir, niacin, or azole antifungals. Physicians considering combined therapy with LIPITOR and fibric acid derivatives, erythromycin, clarithromycin, a combination of ritonavir plus saquinavir or lopinavir plus ritonavir, immunosuppressive drugs, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs (see *Drug Interactions* (7)). Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe myopathy. Prescribing recommendations for interacting agents are summarized in Table 1 [see also *Dosage and Administration, Drug Interactions, Clinical Pharmacology* in full prescribing information].

**Table 1. Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis**

Interacting Agents	Prescribing Recommendations
Cyclosporine	Do not exceed 10 mg atorvastatin daily
Clarithromycin, itraconazole, HIV protease inhibitors (ritonavir plus saquinavir or lopinavir plus ritonavir)	Caution when exceeding doses > 20mg atorvastatin daily. The lowest dose necessary should be used.

**LIPITOR therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and uncontrolled seizures).**

**Liver Dysfunction**—Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. **Persistent elevations (>3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received LIPITOR in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.** One patient in clinical trials developed jaundice. Increases in liver function tests (LFT) in other patients were not associated with jaundice or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of LIPITOR. It is recommended that liver function tests be performed prior to and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Liver enzyme changes generally occur in the first 3 months of treatment with LIPITOR. Patients who develop increased transaminase levels should be monitored until the abnormalities resolve. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of LIPITOR is recommended. LIPITOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of LIPITOR [see *Contraindications* in full prescribing information]. **Endocrine Function**—Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that LIPITOR does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown. Caution should be exercised if a statin is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine. **CNS Toxicity**—Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day. Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0-24 hours) based on the maximum human dose of 80 mg/day. A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0-24) based on the maximum recommended human dose of 80 mg/day. CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class. A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose. **Use in Patients with Recent Stroke or TIA**—In a post-hoc analysis of the Stroke Prevention by Aggressive

Reduction in Cholesterol Levels (SPARCL) study where LIPITOR 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the LIPITOR 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively). The incidence of nonfatal hemorrhagic stroke was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the atorvastatin group [see *Adverse Reactions* in full prescribing information].

**ADVERSE REACTIONS:** The following serious adverse reactions are discussed in greater detail in other sections of the label: Rhabdomyolysis and myopathy [see *Warnings and Precautions* in full prescribing information], Liver enzyme abnormalities [see *Warnings and Precautions* in full prescribing information]

**Clinical Trial Adverse Experiences**—Because clinical trials are conducted under widely varying conditions, the adverse reaction

rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In the LIPITOR placebo-controlled clinical trial database of 16,066 patients (8755 LIPITOR vs. 7311 placebo; age range 10–93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on LIPITOR and 9.5% of the patients on placebo discontinued due to adverse reactions regardless of causality. The five most common adverse reactions in patients treated with LIPITOR that led to treatment discontinuation and occurred at a rate greater than placebo were: myalgia (0.7%), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%). The most commonly reported adverse reactions (incidence  $\geq 2\%$  and greater than placebo) regardless of causality, in patients treated with LIPITOR in placebo controlled trials (n=8755) were: nasopharyngitis (8.3%), arthralgia (6.9%), diarrhea (6.8%), pain in extremity (6.0%), and urinary tract infection (5.7%). Table 2 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in  $\geq 2\%$  and at a rate greater than placebo in patients treated with LIPITOR (n=8755), from seventeen placebo-controlled trials.

**Table 2. Clinical adverse reactions occurring in  $\geq 2\%$  of patients treated with any dose of LIPITOR and at an incidence greater than placebo regardless of causality (% of patients).**

Adverse Reaction*	Any dose N=8755	10 mg N=3908	20 mg N=188	40 mg N=604	80 mg N=4055	Placebo N=7311
Nasopharyngitis	8.3	12.9	5.3	7.0	4.2	8.2
Arthralgia	6.9	8.9	11.7	10.6	4.3	6.5
Diarrhea	6.8	7.3	6.4	14.1	5.2	6.3
Pain in extremity	6.0	8.5	3.7	9.3	3.1	5.9
Urinary tract infection	5.7	6.9	6.4	8.0	4.1	5.6
Dyspepsia	4.7	5.9	3.2	6.0	3.3	4.3
Nausea	4.0	3.7	3.7	7.1	3.8	3.5
Musculoskeletal pain	3.8	5.2	3.2	5.1	2.3	3.6
Muscle Spasms	3.6	4.6	4.8	5.1	2.4	3.0
Myalgia	3.5	3.6	5.9	8.4	2.7	3.1
Insomnia	3.0	2.8	1.1	5.3	2.8	2.9
Pharyngolaryngeal pain	2.3	3.9	1.6	2.8	0.7	2.1

\*Adverse Reaction  $\geq 2\%$  in any dose greater than placebo

Other adverse reactions reported in placebo-controlled studies include: *Body as a whole:* malaise, pyrexia; *Digestive system:* abdominal discomfort, eructation, flatulence, hepatitis, cholestasis; *Musculoskeletal system:* musculoskeletal pain, muscle fatigue, neck pain, joint swelling; *Metabolic and nutritional system:* transaminases increase, liver function test abnormal, blood alkaline phosphatase increase, creatine phosphokinase increase, hyperglycemia; *Nervous system:* nightmare; *Respiratory system:* epistaxis; *Skin and appendages:* urticaria; *Special senses:* vision blurred, tinnitus; *Urogenital system:* white blood cells urine positive.

**Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)**—In ASCOT [see *Clinical Studies* in full prescribing information] involving 10,305 participants (age range 40–80 years, 19% women; 94.6% Caucasians, 2.6% Africans, 1.5% South Asians, 1.3% mixed/other) treated with LIPITOR 10 mg daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with LIPITOR was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up.

**Collaborative Atorvastatin Diabetes Study (CARDS)**—In CARDS [see *Clinical Studies* in full prescribing information] involving 2838 subjects (age range 39–77 years, 32% women; 94.3% Caucasians, 2.4% South Asians, 2.3% Afro-Caribbean, 1.0% other) with type 2 diabetes treated with LIPITOR 10 mg daily (n=1,428) or placebo

(n=1,410), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 3.9 years. No cases of rhabdomyolysis were reported.

**Treating to New Targets Study (TNT)**—In TNT [see *Clinical Studies* in full prescribing information] involving 10,001 subjects (age range 29–78 years, 19% women; 94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident CHD treated with LIPITOR 10 mg daily (n=5006) or LIPITOR 80 mg daily (n=4995), there were more serious adverse reactions and discontinuations due to adverse reactions in the high-dose atorvastatin group (92, 1.8%; 497, 9.9%, respectively) as compared to the low-dose group (69, 1.4%; 404, 8.1%, respectively) during a median follow-up of 4.9 years. Persistent transaminase elevations ( $\geq 3 \times$  ULN twice within 4–10 days) occurred in 62 (1.3%) individuals with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg. Elevations of CK ( $\geq 10 \times$  ULN) were low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%).

**Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study (IDEAL)**—In IDEAL [see *Clinical Studies* in full prescribing information] involving 8888 subjects (age range 26–80 years, 19% women; 99.3% Caucasians, 0.4% Asians, 0.3%

Blacks, 0.04% other) treated with LIPITOR 80 mg/day (n=4439) or simvastatin 20–40 mg daily (n=4449), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 4.8 years.

**Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)**—In SPARCL involving 4731 subjects (age range 21–92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without clinically evident CHD but with a stroke or transient ischemic attack (TIA) within the previous 6 months treated with LIPITOR 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years, there was a higher incidence of persistent hepatic transaminase elevations ( $\geq 3 \times$  ULN twice within 4–10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations of CK ( $>10 \times$  ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%). Diabetes was reported as an adverse reaction in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group [see *Warnings and Precautions* in full prescribing information].

In a post-hoc analysis, LIPITOR 80 mg reduced the incidence of ischemic stroke (218/2365, 9.2% vs. 274/2366, 11.6%) and increased the incidence of hemorrhagic stroke (55/2365, 2.3% vs. 33/2366, 1.4%) compared to placebo. The incidence of fatal hemorrhagic stroke was similar between groups (17 LIPITOR vs. 18 placebo). The incidence of non-fatal hemorrhagic strokes was significantly greater in the atorvastatin group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes). Subjects who entered the study with a hemorrhagic stroke appeared to be at increased risk for hemorrhagic stroke [7 (16%) LIPITOR vs. 2 (4%) placebo].

There were no significant differences between the treatment groups for all-cause mortality: 216 (9.1%) in the LIPITOR 80 mg/day group vs. 211 (8.9%) in the placebo group. The proportions of subjects who experienced cardiovascular death were numerically smaller in the LIPITOR 80 mg group (3.3%) than in the placebo group (4.1%). The proportions of subjects who experienced noncardiovascular death were numerically larger in the LIPITOR 80 mg group (5.0%) than in the placebo group (4.0%).

**Postmarketing Experience**—The following adverse reactions have been identified during postapproval use of LIPITOR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reactions associated with LIPITOR therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following: anaphylaxis, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rhabdomyolysis, fatigue, tendon rupture, hepatic failure, dizziness, memory impairment, depression, and peripheral neuropathy.

**Pediatric Patients (ages 10-17 years)**—In a 26-week controlled study in boys and postmenarchal girls (n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the safety and tolerability profile of LIPITOR 10 to 20 mg daily was generally similar to that of placebo [see *Clinical Studies* in full prescribing information and *Use in Special Populations, Pediatric Use* in full prescribing information].

**OVERDOSAGE:** There is no specific treatment for LIPITOR overdosage. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance LIPITOR clearance.

**Please see full prescribing information for additional information about LIPITOR.**

**Rx only**

Manufactured by:  
**Pfizer Ireland Pharmaceuticals**  
Dublin, Ireland  
Rev. 7 August 2009



Distributed by:

**Parke-Davis**

Division of Pfizer Inc, NY, NY 10017

# DOCTOR'S DIGEST

Your Office in 2015

By Vanessa Geneva Ahern

## ABOUT THE AUTHOR

**V**anessa Geneva Ahern is a freelance writer specializing in health, medicine, and business for consumer and trade magazines. Her writing has appeared in dozens of publications including *Doctor's Digest's* July/August 2007 issue on Emergency Planning, *Fit Pregnancy*, *SELF*, *Specialty Retail Report*, and *Fodor's Publishing*. She is also the founder and editor of *HudsonValleyGoodStuff.com*. Vanessa is based in New York's Hudson Valley.

### ADVISORY BOARD

Jeff Bauer, PhD, Health Futurist, Medical Economist; Author of *Paradox and Imperatives in Health Care: How Efficiency, Effectiveness, and E-Transformation Can Conquer Waste and Optimize Quality and Statistical Analysis for Decision-Makers in Health Care*

Judy Capko, Founder, Capko & Company; Author of *Secrets of the Best-Run Practices*

Paul Martin, DO, Dayton, Ohio

Fred Ralston, Jr., MD, FACP, Fayetteville Medical Associates, Fayetteville, Tenn.; President, American College of Physicians

Susan Wilder, MD, Family Practitioner, Scottsdale, Ariz.; Medical Director, Concierge Choice Physicians

EDITOR Paula S. Katz

SENIOR EDITOR Frank Murphy, Ph.D.

CODING EDITOR Patricia A. Hubbard, CPC

CREATIVE DIRECTOR Gary DeFazio

PRODUCTION DIRECTOR Jane Pickering

PUBLISHER Jeannette Brandofino

MARKETING DIRECTOR Linda Zani Thomas

MARKETING MANAGER Lisa Shevrin

INTELLECTUAL PROPERTY COUNSEL Janet G. Ricciuti, Esq.

The content of *Your Office in 2015*, including such material as text, graphics, images, and other material contained in *Doctor's Digest*, is for informational purposes only. The content is not intended to be a substitute for professional advice. Always seek the advice of professionals with any question you may have. Reliance is at your own risk.

The content of *Your Office in 2015* is protected by copyright under both United States and foreign laws and under United States trademark laws. Title to the content remains with Brandofino Communications, Inc. Any use of the content not expressly authorized by Brandofino Communications, Inc., is a breach of copyright and trademark law. All rights not expressly granted are reserved to Brandofino Communications, Inc.

*Doctor's Digest* (ISSN 1554-6195), November/December, Volume 6, Number 6. Published bimonthly by Brandofino Communications, Inc., 12 Spruce Park, Syosset, NY 11791. For general subscription information and paid subscriptions, e-mail: [doctorsdigest@verizon.net](mailto:doctorsdigest@verizon.net). *Doctor's Digest* is available on a paid subscription basis at the following annual rate: \$54 (foreign, \$108). Single-copy price: \$12. To order, send check or money order payment to *Doctor's Digest*, 12 Spruce Park, Syosset, NY 11791, Attn: Circulation Department (be sure to indicate title of issue, shipping address, and phone number). Visit our Website at [www.doctorsdigest.net](http://www.doctorsdigest.net). For Advertising Sales and Editorial call 516-364-2575 or e-mail [doctorsdigest@verizon.net](mailto:doctorsdigest@verizon.net). Postage paid at Mechanicsburg, PA 17055.

Copyright ©2010 and published by Brandofino Communications, Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means electronic or mechanical, including photocopy, recording, or any information-retrieval system, without permission in writing from the publisher.

*Doctor's Digest*<sup>TM</sup> and the split-diagonal, two-toned publication cover are trademarks of Brandofino Communications, Inc.



# Dear Doctor:

Take a moment to envision your practice in the year 2015. How will you handle the anticipated increase in patients and changes in reimbursement? What will be the must-have technology? This issue of *Doctor's Digest* discusses the foreseeable changes that will have the

most impact on your practice and what you should do now to prepare for them.

Author Vanessa Geneva Ahern starts by talking about healthcare reform's incentives, the timeline for change, and options you should consider now. To make 2015 come alive, she describes what a typical day in the office will be like then, including the role of the medical home and the e-visit. She outlines key standards and rules that experts say are likely to affect your practice. Next she goes into detail about electronic health records and other technology trends. Finally, Vanessa helps you look ahead to green initiatives that may be the norm for your


practice in just a few years.

If you're looking for a change, start with *Doctor's Digest's* new **free** Job/Career Center—**available now** on our Website at [doctorsdigest.net](http://doctorsdigest.net).

I'm excited to announce the *Doctor's Digest* Practice Solution Center™, the first truly interactive practice management solution center. This one-stop resource will be available online, via e-mail, or on the iPad beginning with our January/February issue. You'll find the same content that you've come to rely on, now in the palm of your hand, loaded with interactive features that only digital access can provide including these:

- *Doctor's Digest* SPEED READ—20 Top Practice Management Tips from the current issue
- *Doctor's Digest*—*Money Matters*—Personal finance tips from residency to retirement
- NEW! Job/Career Center—Available on the iPad in January
- REAL TIME! Medication/Hazard Alerts and access to the error-reporting form from the Institute for Safe Medication Practices (ISMP)
- Scroll Strip for easy issue previewing, bookmarking, e-mail, and various search functions

As this cutting-edge practice management tool shows, I remain dedicated to helping you bridge the gap between the practice of medicine and the business of medicine. Let me know what you think. Contact me at [jbrandofino@doctorsdigest.net](mailto:jbrandofino@doctorsdigest.net) or by fax to 516-364-2575.



*Jeannette*

Jeannette Brandofino  
Publisher

e-mail: [jbrandofino@doctorsdigest.net](mailto:jbrandofino@doctorsdigest.net)



# Your Office in 2015

**T**he next few years are likely to be pivotal for your practice. The year 2015 will be a critical time for medical technology—that's when you'll start being penalized for not having an electronic health record (EHR)—and it's also when your office needs to be ready to handle other laws and trends that may impact everything from your business model to the type of paper towel you stock. This issue of *Doctor's Digest* will explore those current and upcoming challenges and will offer practice advice on how you can prepare now to be a best practice in 2015.

We begin by examining the specific impact of healthcare reform on your practice. Next we show you how a 2015 day in the office might play out, starting with your waiting room and continuing through patient follow-up. We explore the effects of e-visits, the patient-centered medical home, and the ethical and legal issues that will be at the forefront.

Next we address changing rules and regulations that will affect your office processes in such areas as emergency management, hazardous and toxic waste, and human resources. Then we look at technology trends in 2015 and address the question of whether EHRs truly herald the advent of a paperless office. Finally, we tell you why you're increasingly likely to have an environmentally friendly office and supply 10 ways to start making your office green today.

## The Impact of Healthcare Reform

8

*Understand how to position your practice to handle changes in payment and a surge of new patients.*

## A Day in the Office

26

*See the impact of changes in patient population and technology by walking through a typical day in a primary care office in 2015.*

## Key Standards and Rules

38

*Discover how changes in standards for measuring clinical success will affect you and your staff.*

## EHRs and Other Tech Trends

60

*Develop realistic expectations for what your EHR system can do as well as how e-visits and cellphones will affect your interactions with patients.*

## The Green Office

70

*Find out how eco-friendly products and construction will become more mainstream and more affordable.*

## For More Information

79